# A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

> **NCT07223138** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **MoonLake Immunotherapeutics AG** · enrollment: 1560 (estimated)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Sonelokimab

## Key facts

- **NCT ID:** NCT07223138
- **Lead sponsor:** MoonLake Immunotherapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-13
- **Primary completion:** 2028-02-04
- **Final completion:** 2028-02-04
- **Target enrollment:** 1560 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223138, "A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07223138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*